Environment
Mixed / Neutral
50%
Benefits
- No direct environmental benefit identified
Risks
- No direct environmental risk identified
FederalUS CongressIntroduced
H.R. 7970: STOP Nitazenes Act
Rep. Robert Latta (R-OH)
H.R. 7970 status: Introduced.
01
What this bill does
Official summary alongside an AI-generated read on where it stands and why.
Overall Score
70OUT OF 100
Score:70/100 civic fit
Risk:Low Risk
Impact:High Impact
Earlier scoring method. Reanalyze to use the sector calculation.
Constitutionality80%
Bipartisan50%
Public opinion70%
Bill summary
No official summary is available for this bill.
02
Impact analysis
✦ AI analysisModeled effects across six domains, estimated from bill text and comparable legislation.
Economy
Mixed / Neutral
50%
Benefits
- May reduce costs associated with drug treatment and law enforcement related to nitazenes.
Risks
- Potential for increased black market activity if enforcement is not effective.
Society
Positive outlook
80%
Benefits
- Permanently schedules dangerous nitazene opioids as Schedule I controlled substances.
- Aims to curb the proliferation and availability of highly potent and lethal synthetic opioids.
- Provides Attorney General with authority to list related substances.
Risks
- Does not address root causes of opioid addiction.
- May not prevent the development of new, unscheduled analogues.
Technology Industry
Not scored in this analysis.
Generate analysis again to evaluate this sector.
Civic Accountability
Not scored in this analysis.
Generate analysis again to evaluate this sector.
Public Health & Safety
Not scored in this analysis.
Generate analysis again to evaluate this sector.
03
How trustworthy & consequential it is
Sourcing already shown above, this is what the analysis found worth flagging.
Confidence
High
Information is complete and verified.
Analysis basis
Full bill text (Congress.gov)
Source used for this bill's analysis.
Warning
The scheduling of these substances may lead to the emergence of new, unscheduled designer drugs.
Analysis scope
The bill relies on the Attorney General to identify and list specific nitazene analogues.
04
Where it stands
Official record- IntroducedCurrent
- CommitteeUpcoming
- House and SenateUpcoming
- Final agreementUpcoming
- PresidentUpcoming
- EnactedUpcoming
05
How it affects your district
✦ Personalized
Set your location
Add your district to see how this bill may affect your community and who to contact.
Your Representatives
Your representatives appear here once you add your location.
06
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.